Myelin Oligodendrocyte Glycoprotein Optic Neuritis in Children
Keywords:
pediatric optic neuritis, acquired demyelinating syndromes.Abstract
Introduction: Optic neuritis is a common presenting feature of paediatric central nervous system demyelinating disease. Pediatric optic neuritis (PON) can present as a unilateral or bilateral acute onset visual loss in children. It occurs in isolation or can be associated with systemic diseases. It has an incidence of two per million children per year and is considered as a different clinical entity compared to adult optic neuritis (AON). This article highlights myelin oligodendrocyte glycoprotein optic neuritis in children and the differences in the course of these two cases. Method: Case report. Results: The first case is a 14-year-old girl who presented to us at the age of 10 with left subacute painless blurring of vision. Funduscopic examination revealed left swollen optic disc with no macula star and right eye optic disc pallor. MRI scans showed demyelinating lesions. The second case was a nine-year-old boy who presented with right painless loss of vision for 1 week with a visual acuity of perception loss. Funduscopic examination showed a blurred margin of the right optic disc with no macula star. MRI brain and spinal cord were suggestive of demyelinating disease. Both cases received high dose intravenous corticosteroid and had good visual recovery. Conclusion: PON often leads to significant visual impairment but typically shows good recovery. An abnormal MRI brain scan at onset or recurring episodes of optic neuritis should prompt clinicians to consider a diagnosis of multiple sclerosis (MS) or neuromyelitis optica (NMO).
References
Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009 Jan 20;72(3):232–9.
Pérez-Cambrodà RJ, Gómez-Hurtado Cubillana A, Merino-Suárez ML, Piñero-Llorens DP, Laria-Ochaita C. Optic neuritis in pediatric population: A review in current tendencies of diagnosis and management. J Optom. 2014 Jul;7(3):125–30.
Yeh EA, Graves JS, Benson LA, Wassmer E, Waldman A. Pediatric optic neuritis. Neurology. 2016 Aug 30;87(9 Supplement 2):S53–8.
Alper G, Wang L. Demyelinating Optic Neuritis in Children. J Child Neurol. 2009 Jan 1;24(1):45–8.
Lana-Peixoto MA, Andrade GC de. The clinical profile of childhood optic neuritis. Arq Neuropsiquiatr. 2001 Jun;59(2B):311–7.
Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006 Jul 25;67(2):258–62.
Lock JH, Newman NJ, Biousse V, Peragallo JH. Update on pediatric optic neuritis. Curr Opin Ophthalmol. 2019 Nov;30(6):418–25.
El-Dairi MA, Ghasia F, Bhatti MT. Pediatric Optic Neuritis. Int Ophthalmol Clin. 2012;52(3):29–49.
Kowsalya A, Ramalingam U, Chaudhary S, Kumar M. Clinical features and visual outcomes of pediatric optic neuritis in the Indian population: A prospective study. Indian J Ophthalmol. 2023;71(2):637.
Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive.A cross sectional study of 132 patients. J Neurol. 2017 Oct 24;264(10):2088–94.
Martinez-Hernandez E, Sepulveda M, Rostásy K, Höftberger R, Graus F, Harvey RJ, et al. Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor α1 Subunit in Patients With Isolated Optic Neuritis. JAMA Neurol. 2015 Feb 1;72(2):187.
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016 Dec 28;13(1):280.
Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, et al. Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Multiple Sclerosis Journal. 2004 Feb 2;10(1):2–4.
Bonhomme GR, Waldman AT, Balcer LJ, Daniels AB, Tennekoon GI, Forman S, et al. Pediatric optic neuritis: Brain MRI abnormalities and risk of multiple sclerosis. Neurology. 2009 Mar 10;72(10):881–5.
Yılmaz Ü, Gücüyener K, Erin DM, Yazar Z, Gürkaş E, Serdaroǧlu A, et al. Reduced Retinal Nerve Fiber Layer Thickness and Macular Volume in Pediatric Multiple Sclerosis. J Child Neurol. 2012 Dec 29;27(12):1517–23.
Yeh EA, Marrie RA, Reginald YA, Buncic JR, Noguera AE, O’Mahony J, et al. Functional-structural correlations in the afferent visual pathway in pediatric demyelination. Neurology. 2014 Dec 2;83(23):2147–52.
Yeh E, Weinstock-Guttman B, Lincoff N, Reynolds J, Weinstock A, Madurai N, et al. Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset. Multiple Sclerosis Journal. 2009 Jul 22;15(7):802–10.
Jayakody H, Bonthius DJ, Longmuir R, Joshi C. Pediatric Optic Neuritis: Does a Prolonged Course of Steroids Reduce Relapses? A Preliminary Study. Pediatr Neurol. 2014 Nov;51(5):721–5.
Kishk NA, Abdelfattah W, Shalaby NM, Shehata HS, Hassan A, Hegazy MI, et al. The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt. BMC Neurol. 2021 Dec 1;21(1).
Downloads
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
